Adalvo, in collaboration with Wyntra announce a significant milestone with the first launch from Adalvo’s Women's Health portfolio in the UK, reinforcing their shared commitment to expanding access to high-quality treatments.

This launch addresses a condition (endometriosis) that affects millions of women worldwide, with an estimated 10% of women of reproductive age impacted—equivalent to approximately 190 million women and girls globally [WHO, 2023]. By bringing this treatment to market, Adalvo and Wyntra are taking an important step in improving care and broadening therapeutic choices for patients and healthcare professionals.

“This launch marks a crucial step in our mission to expand access to high-quality women’s health treatments,” said Anil Okay, CEO of Adalvo. “By leveraging our expertise and strong partnerships, we continue to deliver impactful solutions that address real medical needs.”

Rahul Garella, Co-Founder & CCO of Wyntra , added, “Bringing this treatment to the UK is just the beginning. Together with Adalvo, we are committed to building a strong portfolio that enhances patient care and makes a meaningful difference.”